Stockreport

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc.  (ELTX) 
PDF AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025Poster pre [Read more]